Obatoclax mesylate

N/A

Report date: 2024/07/05 11:15:24
NME

Base Information

Drug NameObatoclax mesylate
Drug Alias Name奥巴妥拉obatoclax奥巴克拉甲磺酸盐CEP-41601 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaPrimary Myelofibrosis +[35] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTeva Pharmaceutical Industries Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGemin X Pharmaceuticals IncNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaPrimary Myelofibrosis +[35] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG